CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,868 | +321.5% | 163,700 | +159.4% | 0.01% | +300.0% |
| Q4 2022 | $1,155 | -99.9% | 63,100 | -27.0% | 0.00% | 0.0% |
| Q2 2022 | $1,611,000 | +347.5% | 86,400 | +238.8% | 0.00% | – |
| Q4 2020 | $360,000 | -42.3% | 25,500 | -28.4% | 0.00% | -100.0% |
| Q2 2020 | $624,000 | – | 35,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
| RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
| Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
| EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
| Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
| Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
| Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
| Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
| Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |